arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Sight Sciences, Inc.

SGHT
$8.51 ▼ -0.09 (-0.99%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
27 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
22
Health
Poor
Bearish
auto_awesome

Analytical Summary

Sight Sciences, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $463.8M
Dividend Yield —
Revenue Growth 19.5% ↗
Op. Margin -16.6% ↗
ROIC -4.7% ↗
FCF / Share $-0.10 ↗
Trailing P/E —
Price / Book 8.8x
FCF Yield —
Debt / Equity 0.77
info Valuation on last close. End-of-day price, Sep 23, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$23.39M
↑ +19.5% —
Net Income Profit after all expenses
$-4.45M
↑ +62.8% —
Operating Margin Operating profit as % of sales
-16.6%
↑ +73.6% 5th
FCF / Share Free cash flow per share
$-0.10
↑ +20.7% —
Long-Term Debt Long-term obligations
$30.64M
↓ -27.7% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
5
Returns ↓
14
Financial Health ↑
38
Cash Quality ↓
53

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 7 years · 27 quarters